SignaCor Therapeutics
ST
Active
· 2024Clinical-stage drug development company advancing treatments for hypertrophic cardiomyopathy and cardiovascular health.
SignaCor Therapeutics
Clinical-stage drug development company advancing treatments for hypertrophic cardiomyopathy and cardiovascular health.
About
SignaCor Therapeutics is a clinical-stage drug development company spun out from Queen's University Belfast. They are developing first-in-class therapies for symptomatic hypertrophic cardiomyopathy (HCM) that target underlying disease pathology to reverse heart damage and improve patient outcomes.
Tags
Performance
Company Timeline
No timeline data for this period
Score Breakdown
10Traction
27Team
60Visibility
7Profile
0Community
0Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does SignaCor Therapeutics do?
SignaCor Therapeutics is a clinical-stage drug development company spun out from Queen's University Belfast. They are developing first-in-class therapies for symptomatic hypertrophic cardiomyopathy (HCM) that target underlying disease pathology to reverse heart damage and improve patient outcomes.
How much funding has SignaCor Therapeutics raised?
SignaCor Therapeutics has raised a total of $315K in funding. The most recent round on record is Seed.
Where is SignaCor Therapeutics headquartered?
SignaCor Therapeutics is headquartered in Belfast, United Kingdom.
When was SignaCor Therapeutics founded?
SignaCor Therapeutics was founded in 2024.
What industry does SignaCor Therapeutics operate in?
SignaCor Therapeutics operates in HealthTech, Biotechnology, Cardiovascular Health, Cardiovascular.
Contact Info
Location
Belfast, United Kingdom
Similar Startups